Charles River Laboratories Announces Second-Quarter 2015 Results from Continuing Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
July 30, 2015 7:13 AM EDTCharles River Laboratorie (NYSE: CRL) reported Q2 EPS of $0.96, $0.01 worse than the analyst estimate of $0.97. Revenue for the quarter came in at $339.6 million versus the consensus estimate of $338.3 million.
Charles River Laboratorie sees FY2015 EPS of $3.60-$3.70, versus the consensus of $3.64.
The company also announced announced that it has extended its initial three-year partnership with AstraZeneca (NYSE:... More
